Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CLBS12 · 1 trial · 4 indications
CLI-free is determined by assessing the Rutherford score (\</=3) by the investigator and a central adjudication committee.
| Arm | Type | Description |
|---|---|---|
| CLI Due to ASO with CLBS12 + SOC | EXPERIMENTAL | This group of subjects with CLI due to ASO will be administered with CLBS12 + SOC for collecting efficacy and safety data. |
| CLI Due to ASO with SOC | ACTIVE_COMPARATOR | This group of subjects with CLI due to ASO will be administered with SOC only. |
| CLI Due to BD with CLBS12 | EXPERIMENTAL | CLBS12 will be administered to patients with CLI due to BD for collecting safety and efficacy data. |
| Name | Type | Description |
|---|---|---|
| CLBS12 | BIOLOGICAL | Intramuscular transfusion of CLBS12. |
| SOC | DRUG | Standard of care (SOC) is defined as pharmacotherapy with approved drugs (e.g., antiplatelets, anticoagulants, and vasodilators including prostanoids). |
Inclusion Criteria: * subject has CLI caused by ASO or BD Exclusion Criteria: * \< 20 years old
CLBS12 is an investigational biologic therapy developed by Lisata Therapeutics for critical limb ischemia, a severe form of peripheral artery disease. It has been studied in a Phase 2 clinical trial conducted in Japan that enrolled 33 patients with critical limb ischemia and related vascular conditions.
CLBS12 is being developed for the treatment of critical limb ischemia, a condition in which blood flow to the limbs is severely reduced. The Phase 2 study of CLBS12 also enrolled patients with Buerger disease, also called thromboangiitis obliterans, and atherosclerosis obliterans.
CLBS12 is being developed by Lisata Therapeutics, Inc., a company whose common stock trades under the ticker symbol LSTA. Lisata Therapeutics sponsored the Phase 2 clinical study of CLBS12 in critical limb ischemia conducted in Japan.
CLBS12 is in Phase 2 clinical development. Its single registered trial, NCT02501018, is a completed Phase 2 study. CLBS12 is investigational and has not been established as an approved therapy for critical limb ischemia.
CLBS12 has been evaluated in one clinical trial, NCT02501018, titled a Study to Assess the Efficacy and Safety of CLBS12 in Patients with Critical Limb Ischemia. The Phase 2 trial was active-controlled, randomized, enrolled 33 patients in Japan, and is now completed.